Unichem Laboratories Ltd

Unichem Laboratories Ltd share price ticked higher by 0.04% to Rs 504.35 after the company's net profit tumbled by 46.42% to Rs 22.22 crore, while revenue from operations slightly gained 1.20% to Rs 640.22 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.73 lakh crore, gaining 4.49%. It has improved by 1.84% over last one week and ticked higher by 1.37% in last one month while the market capitalization of Unichem Laboratories Ltd has inched up 3.66% and 1.61% in the same period respectively. Profit before tax (PBT) of Unichem Laboratories Ltd stood at Rs 27.37 crore in Q3 FY26, crashing by 352.96% year-on-year, and tanking 44.13% quarter-on-quarter. EBITDA came in at Rs 59 crore, expanding by 30.70% YoY and rising 8.76% sequentially. Total expenses posted a minor rise of 0.61% to Rs 596.25 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 255.11 crore, soaring by 34.25% YoY, while employee benefits expense was at Rs 105.57 crore, ticking higher by 2.19% YoY. For the TTM ended FY26, revenue from operations inched higher 4.31% to Rs 2201.85 crore, while net profit jumped 83.86% to Rs 252.84 crore, compared to previous TTM. EBITDA jumped by 22910% to Rs 121.11 crore, and PBT soared 89.13% to Rs 292.38 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 3.64 crore in FY26, as against Rs 7.02 crore in FY25. Unichem Laboratories Ltd rose by 6.30% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 8.41% during the same period.

Unichem Laboratories Ltd. will hold a board meeting on Wednesday, November 4, 2026, to consider and approve the unaudited financial results (consolidated and standalone) for the second quarter and six months ended September 30, 2026, as per a regulatory filing.

Unichem Laboratories Limited informed the BSE Ltd and National Stock Exchange of India Ltd that MUFG Intime India Private Limited, formerly Link Intime India Private Limited, issued a compliance certificate dated October 3, 2026, confirming adherence to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.

Unichem Laboratories Ltd. announced that the trading window for dealing in the company's shares will be closed from October 1, 2026, for designated persons, directors, insiders, and their immediate relatives, according to a filing with the BSE Ltd. and National Stock Exchange of India. The window will reopen 48 hours after the unaudited financial results for the quarter and half year ended September 30, 2026, are made public.

Unichem Laboratories Ltd share price ticked higher by 4.05% to Rs 507.95 after the company's net profit surged by 280.11% to Rs 41.47 crore, while revenue from operations increased 10% to Rs 632.62 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.56 lakh crore, easing 4.63%. It has improved by 0.56% over last one week and heading higher by 13.27% in last one month while the market capitalization of Unichem Laboratories Ltd has inched up 1.65% and 40.05% in the same period respectively. Profit before tax (PBT) of Unichem Laboratories Ltd stood at Rs 48.99 crore in Q2 FY26, nosediving by 643.13% year-on-year, and surging by 160.72% quarter-on-quarter. EBITDA came in at Rs 54 crore, jumping 246.71% YoY and rallying 124.41% sequentially. Total expenses saw a slight increase of 6.19% to Rs 592.62 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 190.02 crore, inching up 3.25% YoY, while employee benefits expense was at Rs 103.31 crore, improving by 11.27% YoY. For the TTM ended FY26, revenue from operations tick up 4.31% to Rs 2201.85 crore, while net profit jumped 83.86% to Rs 252.84 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 22910% to Rs 121.11 crore, and PBT surged 89.13% to Rs 292.38 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 3.64 crore in FY26, as against Rs 7.02 crore in FY25. Unichem Laboratories Ltd inched up 3.10% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 2.56% during the same period.

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 11 August 2026.

Unichem Laboratories announced that the 63th Annual General Meeting(AGM) of the company will be held on 11 August 2026.

Net profit of Unichem Laboratories declined 79.40% to Rs 10.91 crore in the quarter ended March 2026 as against Rs 52.97 crore during the previous quarter ended March 2025. Sales declined 2.05% to Rs 575.12 crore in the quarter ended March 2026 as against Rs 587.18 crore during the previous quarter ended March 2025. For the full year,net profit rose 83.86% to Rs 252.84 crore in the year ended March 2026 as against Rs 137.52 crore during the previous year ended March 2025. Sales rose 4.31% to Rs 2201.85 crore in the year ended March 2026 as against Rs 2110.97 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales575.12587.18 -2 2201.852110.97 4 OPM %8.2914.25 -8.3612.55 - PBDT61.7687.49 -29 215.64279.15 -23 PBT31.1557.80 -46 90.52154.59 -41 NP10.9152.97 -79 252.84137.52 84 Powered by Capital Market - Live

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 22 May 2026.

Net profit of Unichem Laboratories rose 356.85% to Rs 264.29 crore in the quarter ended December 2025 as against Rs 57.85 crore during the previous quarter ended December 2024. Sales declined 2.24% to Rs 521.17 crore in the quarter ended December 2025 as against Rs 533.09 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales521.17533.09 -2 OPM %8.5916.04 - PBDT49.1692.39 -47 PBT17.9161.85 -71 NP264.2957.85 357 Powered by Capital Market - Live